New hypolipidemic drugs from the group of reductase inhibitors GMG-CoA

Por A V Susekov, M Yu Zubareva, V V Kukharchuk
Publicado em 2003-02-01

Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the leve...

Por A. V. Susekov, M. Yu. Zubareva, T. A. Rozhkova, V. P. Masenko
Publicado em 2011-12-01

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with in...

Por M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva, A. V. Susekov
Publicado em 2010-12-01

Efficacy and safety of Mertenil (rosuvastatin) 40 mg in patients with familial hypercholesterolemia

Por M Yu Zubareva, P P Malyshev, T A Rozhkova, V V Kuharchuk
Publicado em 2014-06-01

Double cholesterol inhibition — a new approach to effective control of hyperlipidemia and atherosclerosis

Por A. V. Susekov, N. B. Gornyakova, M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva
Publicado em 2009-12-01

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen l...

Por A. V. Susekov, M. Yu. Zubareva, M. I. Tripoten’, T. A. Rozhkova, O. A. Pogorelova, T. V. Balakhonova, V. P. Masenko, V. V. Kukharchuk
Publicado em 2006-12-01

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness

Por A. V. Susekov, T. A. Rozhkova, M. I. Tripoten’, O. A. Pogorelova, B. D. Kulev, T. V. Balakhonova, M. Yu. Zubareva, V. P. Masenko, A. N. Rogoza, V. V. Kukharchuk
Publicado em 2007-06-01